XIII Annual INFOTEHNA Pharmaceutical Conference

25 - 27 May 2011, Wörthersee/Klagenfurt, Austria.
INFOTEHNA Group, leading provider of Software Solutions for Pharmaceutical Industry, is organizing its traditional (XIII) Annual Pharmaceutical Conference. Event will take place at idyllic alpine lake Woerthersee in southern Austria.

INFOTEHNA's consultants with guest speakers from Agencies and successful pharmaceutical companies will focus on areas of Regulatory Affairs, Research & Development, Quality Assurance and Quality Control.

Pre-conference day - May 25
Pre-conference day will be devided in two workshops: to newcomers INFOTEHNA's software solutions for faster, easier and efficient work with documentation will be presented, along with several case studies. To loyal customers, INFOTEHNA will unveil new functions of our system, some tricks of Submission Management and show demonstration of Training Management Tool. Event organisers will discuss Pharmacovigilance Documentation in electronic system, connection with Regulatory Authorities and much more.

Conference day - May 26
Speakers from successful Pharma companies and Regulatory Agencies will share their experiences and knowledge in 2 Streams:

1) Regulatory Affairs and Pharmacovigilance
2) Quality and Development

In Hands-on corner you will be able to work with INFOTEHNA's system and test its functionalities, consult experts and get answers to any questions concerning the use of INFOTEHNA's solutions.

For further information and registration, please visit:
http://www.infotehna.com/event/373

About INFOTEHNA
INFOTEHNA Group is with more than 20 years in the industry well established provider of hi-end Enterprise Content Management Software, delivering totally integrated solutions for mission-critical business processes in pharmaceutical industry. They are ready to validate and deploy without expensive customization, and designed with compliance regulations and best practices in mind.

INFOTEHNA Expert Series solutions have over 5000 users in more than 20 countries. With offices in Germany, USA, India, Turkey, Slovenia and Croatia, INFOTEHNA is globally present and highly experienced partner of world's largest Life Science companies.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...